Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Imlifidase (Idefirix) for Desensitization of highly sensitized adults before deceased-donor kidney transplant

Hansa Biopharma · BLA
FDA decision due
Dec 192026
29 days away
December has 9 FDA decisions on our calendar, this one included. Before it, Tirabrutinib on Dec 18th. After it, Anito-cel on Dec 23rd.

The FDA is expected to decide on Imlifidase for Desensitization of highly sensitized adults before deceased-donor kidney transplant by December 19, 2026, under a BLA from Hansa Biopharma.

What the FDA is deciding on Imlifidase

The FDA is reviewing Hansa Biopharma's application to approve Imlifidase (Idefirix) for desensitization of highly sensitized adults before deceased-donor kidney transplant.

An enzyme from Streptococcus pyogenes, given as a single infusion hours before transplant, that cleaves IgG antibodies so a highly sensitized patient (cPRA 99.9% or higher, with a positive crossmatch) can receive a kidney that their immune system would otherwise reject immediately. These patients make up an estimated 10-15% of the transplant waiting list and can wait indefinitely on dialysis.

Holds Fast Track and Orphan Drug designations; Hansa requested priority review, and the FDA later set a December 19, 2026 action date, 12 months after the December 2025 submission. In the 64-patient US Phase 3 ConfIdeS trial, average kidney function (eGFR) at 12 months was 51.5 with imlifidase versus 19.3 in the control arm, and significantly more patients were off dialysis.

Would be the first US treatment for this group; conditionally approved in the EU and UK as Idefirix since 2020.

What an approval or a rejection of Imlifidase would mean

An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.

A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.

Frequently asked questions

When will the FDA decide on Imlifidase?

The FDA's target date (PDUFA date) for Imlifidase in Desensitization of highly sensitized adults before deceased-donor kidney transplant is December 19, 2026.

Who disclosed it: Hansa Biopharma. The FDA does not publish these dates.

Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.

Source: Hansa Biopharma press release

What is Imlifidase being reviewed for?

Hansa Biopharma submitted a BLA for Imlifidase in Desensitization of highly sensitized adults before deceased-donor kidney transplant.

What to know: An enzyme from Streptococcus pyogenes, given as a single infusion hours before transplant, that cleaves IgG antibodies so a highly sensitized patient (cPRA 99.9% or higher, with a positive crossmatch) can receive a kidney that their immune system would otherwise reject immediately. These patients make up an estimated 10-15% of the transplant waiting list and can wait indefinitely on dialysis. Holds Fast Track and Orphan Drug designations; Hansa requested priority review, and the FDA later set a December 19, 2026 action date, 12 months after the December 2025 submission. In the 64-patient US Phase 3 ConfIdeS trial, average kidney function (eGFR) at 12 months was 51.5 with imlifidase versus 19.3 in the control arm, and significantly more patients were off dialysis. Would be the first US treatment for this group; conditionally approved in the EU and UK as Idefirix since 2020.

How much will Imlifidase cost?

Hansa Biopharma has not announced a price. Drugmakers usually set it around approval.

Help paying: drugmaker programs and charity funds usually open at launch.

Find help: the patient assistance finder lists programs by insurance type.

What happens after the Imlifidase decision?

This page updates with the outcome the day it is announced.

If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.

If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.

Where this date comes from

The FDA does not publish PDUFA dates; companies disclose them. This one comes from Hansa Biopharma press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.